Alexander Sotnikov
Berater
30 Jahre alt
Berufliche Stellung
Studentin
Auf der Suche nach einer Praktikumsstelle
Student Botschafterin
London School of Economics and Political Science
Seit November 2016
Ehrenamtlliche Arbeit
- Förderung des Programms für Interessenten: Teilnahme an einem Informations-Session-Event, um Fragen von Interessenten zu beantworten
- Verbinden mit Angebotsinhabern: Senden von individuellen Willkommens-E-Mails an die Inhaber und Beantwortung ihrer Fragen über laufende E-Mail-Korrespondenz im Vorfeld bis zum Beginn des Programms.
Intern in Investitionsabteilung
Human Stem Cells Institute OJSC
August 2016
Praktikum
- Suchte nach potenziellen Investoren in Hongkong und Singapur, kontaktierte sie und stellte ihnen die Werbematerialien zur Verfügung
- Ich habe Verbesserungen in der PowerPoint-Präsentation für Investoren aufgrund der Unzulänglichkeiten des Designs vorgestellt und die Aufmerksamkeit auf die fehlenden Informationen zu Schlüsselthemen wie Marktforschung, Schutz der Patente über Russland, die Wachstumsaussichten der Medizin gelenkt
- Übersetzte Werbematerialien
Beschreibung des Unternehmens
Human Stem Cells Institute PJSC (HSCI) is a Russian public biotech company founded in 2003.
HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.
The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.
HSCI owns the largest family cord blood stem cell bank in Russia and the CIS – Gemabank®, as well as the reproductive cell and tissue bank Reprobank® (personal storage and donation).
The Company launched Neovasculgen®, the first-in-class gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy®, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
HSCI is implementing a socially significant Genetico® project for the development of its own Medical genetics center & lab to provide a wide range of genetic testing and counseling services with the aim of early identification, prediction and prophylactic treatment of genetic disorders, including reproductive system diseases (e.g. PGS/PGD, NIPT, Oncogenetics, Bioinformatics, diagnostic panels for specific disease categories and cases).
The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.
HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.
HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.
The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.
HSCI owns the largest family cord blood stem cell bank in Russia and the CIS – Gemabank®, as well as the reproductive cell and tissue bank Reprobank® (personal storage and donation).
The Company launched Neovasculgen®, the first-in-class gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy®, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
HSCI is implementing a socially significant Genetico® project for the development of its own Medical genetics center & lab to provide a wide range of genetic testing and counseling services with the aim of early identification, prediction and prophylactic treatment of genetic disorders, including reproductive system diseases (e.g. PGS/PGD, NIPT, Oncogenetics, Bioinformatics, diagnostic panels for specific disease categories and cases).
The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.
HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.
Website des Unternehmens
Hochschulausschuss Panel Freiwilliger
King’s College London
Oktober 2014
bis Mai 2016
Ehrenamtlliche Arbeit
- In der Position der Verantwortung für die Entscheidung über das Ergebnis von Studenten Fällen (Appelle, Fehlverhalten, Fitness-to-Practice für Krankenschwestern und Hebammen)
- Brachte die Schülerperspektive auf die Diskussion, die die Meinung anderer Panelmitglieder veränderte und schließlich das Ergebnis des Falles änderte
- Beschmutzte Inkonsistenzen in der Antwort eines Studenten oder der Universität und vermittelte sie in sensibler und verständlicher Weise dem Komitee
3. Jahr Business Management Studenten Vertreter
King’s College London
Oktober 2015
bis Mai 2016
Ehrenamtlliche Arbeit
- Als studentischer Vertreter unter einem Pool von 10 Kandidaten gewählt, um 150 Kursteilnehmer zu vertreten
- Als Vermittler zwischen Studenten und der Abteilung gehandelt, indem sie Fragen wie Vortragserklärung, Feedback-Verbesserung und mangelhafte Politik bei der Auswahl der Module
- I hatte nicht übertrieben. I hatte alle Schüler auf dem Laufenden über die Antwort der Abteilung
erstellt